

Special Issue

Pathological Mechanism of Breast Cancer

Message from the Guest Editor

Breast cancer stands as the most prevalent malignancy diagnosed, impacting countless individuals, and the leading cause of cancer-related death among women, making it a global issue. Reasonably, gaining a comprehensive understanding of the intricate pathological mechanisms underpinning breast cancer initiation, progression, metastasis, and treatment resistance emerges as paramount. Recently, there has been a surge in the exploration of innovative therapeutic targets, biomarkers, and diagnostic tools, which encompasses the integration of liquid biopsy, genomics, proteomics, single-cell analysis, and artificial intelligence. These endeavors are driven by the necessity to enhance patient outcomes and customize treatment strategies to individual needs. This Special Issue aims to spotlight the recent strides in the pathological mechanisms of breast cancer evolution and treatment, addressing the multitude of lingering questions that remain to be addressed. We encourage authors to submit original articles or review papers focusing on the intricate pathological mechanisms of breast cancer.


Guest Editor

Dr. Mariia Ivanova

Division of Pathology, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy

Deadline for manuscript submissions

25 January 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/204349

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).